U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4 – Sarepta Therapeutics
The U.S. Food and Drug Administration (FDA) has recently granted Platform Technology Designation to the viral vector used in SRP-9003, an investigatio…
Leggi tutto